PRLD(PRLD)
PRLD
10/14/26
Prelude Therapeutics (PRLD)
Wednesday
3:10 PM
ThesisRecent positive clinical trial results and potential partnership developments are enhancing investor sentiment towards Prelude Therapeutics.
Revenue Outlook
Why Revenue Could Explode
- 01Recent clinical trial data for PRT543 shows a 45% response rate in patients with specific genetic mutations.
- 02Partnership discussions with a major pharmaceutical company are reportedly advancing, potentially leading to a lucrative collaboration deal.
- 03The company has successfully completed a $50 million financing round to support ongoing clinical trials.
- 04Potential for PRT811 to enter late-stage trials earlier than anticipated due to positive interim results.
- 05Precision medicine in oncology
- 06Increased investment in biotech R&D
- 07Clinical trial results for lead candidates PRT543 and PRT811
- 08Partnership announcements with larger pharmaceutical companies
FY2025 Snapshot
- Revenue
- $12M
- Rev. Growth
- +73.4%
- Gross Margin
- 85.9%
- Op. Margin
- -861%
- Net Margin
- -820%
- Net Income
- $-99M
- NI Growth
- +21.8%
- EPS
- $-1.29
- 1Y Return
- +183%
PRLD Chart
My Notes
- "The recent data underscores our commitment to precision medicine in oncology."
- Moat: Prelude's focus on precision oncology and proprietary drug discovery platform provides a competitive edge…
- growth - Investors are likely attracted to the high potential upside from successful drug development.
- Moderate.
- Watch on earnings: Clinical trial enrollment rates, Partnership revenue milestones, Cash burn rate.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $43M to $36M as recent clinical trial data for prt543 shows a 45% response rate in patients with specific genetic mutations.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.
Explore More
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance
